IP Library Patent Application 12048771
Patent Application
App. No. 12/048,771

Transdermal Delivery Form Disposal Systems and Methods

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/048,771
Abstract

The extraction and use of residual opioids from transdermal dosage forms can be reduced by placement and fixation of used dosage forms onto a surface. The used dosage form can be fixed to the surface such that it cannot be removed without at least partially destroying the matrix containing the opioid, or such that the matrix containing the opioid is rendered at least partially inaccessible to opioid extraction methods. The disposal system for one or more opioid-containing transdermal delivery forms comprises at least one disposal surface for receiving the transdermal delivery form. The at least one disposal surface can comprise one or more structures for fixing a transdermal delivery form to the at least one surface. Alternatively, the transdermal delivery form comprises one or more structures for permanently fixing the transdermal delivery form to the surface. The disposal system can also be used for preventing or reducing diversion of opioids from transdermal delivery forms.

Claims (28)

1 . A disposal system for one or more used transdermal delivery forms containing controlled substances, comprising at least one disposal surface for receiving the one or more used transdermal delivery forms and one or more structures for fixing the transdermal delivery form to the disposal surface.

2 . The disposal system of claim 1 , wherein the one or more structures for fixing the used transdermal delivery form to the disposal surface are located on or attached to the at least one disposal surface.

3 . The disposal system of claim 1 , wherein the one or more used transdermal delivery forms comprise a reservoir for the controlled substance.

4 . The disposal system of claim 1 , wherein the one or more structures for permanently fixing the transdermal delivery form to the disposal surface are located on or attached to the one or more used transdermal delivery forms.

5 . The disposal system of claim 1 , wherein the one or more used transdermal delivery forms comprise an opioid.

6 . The disposal system of claim 5 , wherein the opioid is selected from the group consisting of alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, fentanyl congeners, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, tilidine, tramadol, the pharmaceutically acceptable acid addition salts thereof, and any combinations of these.

7 . The disposal system of claim 6 , wherein the fentanyl congeners are at least one selected from the group consisting of sufentanil, alfentanil, lofentanil, carfentanil, remifentanil, trefentanil and mirfentanil.

8 . The disposal system of claim 1 , wherein the one or more used transdermal delivery forms further comprise a salicylate, acetaminophen, phenylpropanolamine, phenylephrine, chlorpheniramine, caffeine or guaifenesin.

9 . The disposal system of claim 1 , wherein the one or more used transdermal delivery forms comprise adhesive disposed on substantially the entire surface intended to contact the skin or disposed around substantially the entire perimeter of the surface intended to contact the skin.

10 . The disposal system of claim 1 , wherein the at least one disposal surface comprises one or more defined areas for receiving the one or more used transdermal delivery forms.

11 . The disposal system of claim 10 , wherein the defined areas are identified by markings which correspond with the one or more transdermal delivery forms.

12 . The disposal system of claim 1 , wherein the one or more structures for fixing the transdermal delivery form to the disposal surface comprise one or more adhesives disposed on the at least one disposal surface.

13 . The disposal system of claim 1 , wherein the one or more structures for fixing the transdermal delivery form to the disposal surface comprise a fastening device.

14 . The disposal system of claim 1 , wherein the one or more structures for fixing the transdermal delivery form to the disposal surface comprise at least one covering layer.

15 . The disposal system of claim 14 , wherein the at least one covering layer comprises one or more adhesives.

16 . The disposal system of claim 1 , wherein the used transdermal delivery forms comprise at least one substance which reduce the oral, intranasal or parenteral effectiveness of controlled substances extracted from the used transdermal delivery forms.

17 . The disposal system of claim 16 , wherein the substance is an opioid antagonist, capsaicin or a capsaicinoid.

18 . A method of disposing of one or more used transdermal delivery forms containing controlled substances comprising:

(1) providing the disposal system of claim 1 ;

(2) placing one or more used transdermal delivery forms on the at least one disposal surface; and

(3) fixing the one or more used transdermal delivery forms to the at least one disposal surface.

19 . A method to reduce or prevent diversion of controlled substances contained in one or more used transdermal delivery forms, comprising:

(1) providing the disposal system of claim 1 ;

(2) placing one or more used transdermal delivery forms on the at least one disposal surface; and

(3) fixing the one or more used transdermal delivery forms to the at least one disposal surface.

20 . A method of producing a disposal system for one or more used transdermal delivery forms containing a controlled substance comprising:

forming at least one disposal surface for receiving the one or more used transdermal delivery forms; and

associating the one or more structures for fixing the one or more used transdermal delivery forms to the at least one disposal surface with the at least one disposal surface.

Assignments (7)
RELEASE OF PATENT SECURITY INTEREST Recorded Mar 3, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 032380/0198 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 25416/381 Recorded Jul 11, 2011
From: JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 026572/0148 →
SECURITY AGREEMENT Recorded Jul 7, 2011
From: ENDO PHARMACEUTICALS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 026557/0350 →
RELEASE OF PATENT SECURITY INTEREST RECORDED AT REEL/FRAME 23390/120 Recorded Dec 3, 2010
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 025441/0305 →
SECURITY AGREEMENT Recorded Dec 1, 2010
From: ENDO PHARMACEUTICALS INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 025416/0381 →
SECURITY AGREEMENT Recorded Oct 19, 2009
From: ENDO PHARMACEUTICALS INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 023390/0120 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2008
From: GOLDBERG, ALAN P.
To: ENDO PHARMACEUTICALS, INC.
Reel/Frame 020776/0229 →